Prediction markets have expanded into pharmaceutical clinical trials, allowing users to wager on the outcomes of medical research and federal drug approvals.
Startmag reported that platforms such as Kalshi and Polymarket now transform drug development milestones into financial contracts where participants win or lose money based on regulatory decisions by the Food and Drug Administration. The financial expansion turns complex medical evaluations into speculative assets, drawing sharp warnings from scientific journals and prompting inquiries from lawmakers in Washington.
Kalshi launched a pilot program in July in collaboration with artificial intelligence firm AppliedXL to facilitate wagers on clinical trial results and regulatory decisions. Polymarket hosts similar international contracts outside the direct regulatory oversight of United States authorities.
Under the mechanics of these prediction markets, a contract typically pays one dollar if a specific event occurs and zero if it fails, with the trading price reflecting the market’s perceived probability of success.
Proponents argue that aggregating market insights can unearth hidden information within the pharmaceutical sector. “Development of drugs is one of the most important sectors in the world and, at the same time, one of those in where the information available is most limited,” said Tarek Mansour, CEO of Kalshi, defending the initiative as a tool to improve forecasting and direct capital toward promising treatments.
Researchers and medical journals caution that the system creates severe vulnerabilities, including insider trading and trial manipulation. Individuals with privileged access—such as researchers, clinical investigators, pharmaceutical employees, and FDA personnel—may possess trial outcomes long before public release. Entities with financial stakes in a drug's development could theoretically attempt to influence small-scale trials where the classification of a single adverse event can alter an entire research endpoint.
Patients participating in clinical trials also face potential fallout from these speculative odds. Published market probabilities might discourage recruitment for trials deemed unlikely to succeed or inflate expectations for failing therapies, ultimately risking data integrity and patient adherence.
The lawmakers requested internal communications regarding employee participation in such wagers and details on interactions with platforms and the Commodity Futures Trading Commission.
“Allowing individuals to gamble on the success of these trials and these drugs undermines the scientific process, creates perverse incentives for researchers, harms study participants, and could cause dangerous medical consequences for countless Americans,” the senators wrote.
Kalshi said that it has enacted safeguards, including limiting contracts to late-stage trials and conducting insider checks, though the firm has weighed expanding offerings to early-stage studies and adverse event tracking. As these platforms grow, researchers continue to press for tighter controls to safeguard medical science from speculative pressures.
